{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["24(8)"],"submitter":["Verheye S"],"funding":["Elixir Medical Corporation"],"pubmed_abstract":["<h4>Background</h4>The DynamX Novolimus-Eluting Coronary Bioadaptor System ( DynamX ®  Bioadaptor) has uncaging elements that disengage after the resorption of the polymer coating, aiming to restore vessel function in the treated segment and to avoid long-term adverse outcomes associated with the permanent caging of the coronary artery seen with conventional stenting.<h4>Methods</h4>This prospective, multicenter, single-arm first-in-human study enrolled 50 patients in Belgium and Italy who were treated with the DynamX Bioadaptor. Eligible patients had <i>de novo</i> lesions in coronary arteries measuring between 2.5 and 3.5 mm in diameter and ≤ 24 mm in length. Clinical follow-up was performed up to 36 months. This analysis includes the intention-to-treat population and is based on data av"],"journal":["Reviews in cardiovascular medicine"],"pagination":["221"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11266769"],"repository":["biostudies-literature"],"pubmed_title":["Final 36-Month Outcomes from the Multicenter DynamX Study Evaluating a Novel Thin-Strut Novolimus-Eluting Coronary Bioadaptor System and Supporting Preclinical Data."],"pmcid":["PMC11266769"],"pubmed_authors":["De Bruyne B","Abizaid A","Giannini F","Verheye S","Costa RA","Colombo A","Bedogni F","Dubois C","Costa JR","Vrolix M","Montorfano M","Chamie D"],"additional_accession":[]},"is_claimable":false,"name":"Final 36-Month Outcomes from the Multicenter DynamX Study Evaluating a Novel Thin-Strut Novolimus-Eluting Coronary Bioadaptor System and Supporting Preclinical Data.","description":"<h4>Background</h4>The DynamX Novolimus-Eluting Coronary Bioadaptor System ( DynamX ®  Bioadaptor) has uncaging elements that disengage after the resorption of the polymer coating, aiming to restore vessel function in the treated segment and to avoid long-term adverse outcomes associated with the permanent caging of the coronary artery seen with conventional stenting.<h4>Methods</h4>This prospective, multicenter, single-arm first-in-human study enrolled 50 patients in Belgium and Italy who were treated with the DynamX Bioadaptor. Eligible patients had <i>de novo</i> lesions in coronary arteries measuring between 2.5 and 3.5 mm in diameter and ≤ 24 mm in length. Clinical follow-up was performed up to 36 months. This analysis includes the intention-to-treat population and is based on data av","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2026-06-01T07:41:46.06Z","creation":"2026-04-08T10:34:30.341Z"},"accession":"S-EPMC11266769","cross_references":{"pubmed":["39076703"],"doi":["10.31083/j.rcm2408221"]}}